The £115m price tag had seemed to hang around his neck like a glittering weight in his early days at Chelsea but we're now ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded ...

Experts recommend eating foods high in probiotics before taking a supplement for weight loss, but supplements can help fill ...

After hitting a record high, the U.S. rate of obesity is falling, as the number of people taking GLP-1 medications rises ...

Gallup’s latest health index links the rapid rise of semaglutide and similar injectables to measurable population-level weight loss.

Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global demand ahead of a potential launch next year.

VISALIA, Calif (KFSN) -- For the first time in over a decade, obesity rates in the US are down, from 39% to 37.7%. Meanwhile, ...

The Gallup National Health and Well-Being Index shows that GLP-1 weight loss drugs are having an effect: The U.S. obesity ...

GLP-1 drugs were initially developed for type 2 diabetes but are now widely used to treat obesity. Novo Nordisk and Eli Lilly lead in GLP-1 drug production, with others like Viking Therapeutics ...